

Cassiana Mendes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1415214/publications.pdf>

Version: 2024-02-01

28
papers

327
citations

840585

11
h-index

887953

17
g-index

28
all docs

28
docs citations

28
times ranked

560
citing authors

#	ARTICLE	IF	CITATIONS
1	Blended polymeric films containing the drugs simvastatin and resveratrol: The supersaturation approach for melanoma treatment. <i>Colloids and Interface Science Communications</i> , 2022, 46, 100501.	2.0	0
2	Supersaturating drug delivery systems containing fixed-dose combination of two antihypertensive drugs: Formulation, in vitro evaluation and molecular metadynamics simulations. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 163, 105860.	1.9	7
3	New supersaturating drug delivery system as strategy to improve apparent solubility of candesartan cilexetil in biorelevant medium. <i>Pharmaceutical Development and Technology</i> , 2020, 25, 89-99.	1.1	6
4	Understanding the interaction between Soluplus® and biorelevant media components. <i>Colloids and Surfaces B: Biointerfaces</i> , 2020, 187, 110673.	2.5	11
5	Impact of Drug-Polymer Interaction in Amorphous Solid Dispersion Aiming for the Supersaturation of Poorly Soluble Drug in Biorelevant Medium. <i>AAPS PharmSciTech</i> , 2020, 21, 189.	1.5	5
6	Determination of Hydrochlorothiazide and Two Major Degradation Products by Stability Indicating High Performance Liquid Chromatography. <i>Current Pharmaceutical Analysis</i> , 2020, 16, 176-180.	0.3	2
7	Supersaturating drug delivery system of fixed drug combination: sulfamethoxazole and trimethoprim. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 841-850.	2.0	10
8	Carbamide peroxide nanoparticles for dental whitening application: Characterization, stability and in vivo/in situ evaluation. <i>Colloids and Surfaces B: Biointerfaces</i> , 2019, 179, 326-333.	2.5	19
9	Intestinal permeability enhancement of benzopyran HP1-loaded nanoemulsions. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 127, 115-120.	1.9	7
10	A Simple, Green and Fast Ultraviolet Spectrophotometric Method for the Carbamide Peroxide Determination in Dental Whitening Products. <i>Current Pharmaceutical Analysis</i> , 2019, 15, 138-144.	0.3	2
11	7-nitroindazol-loaded nanoemulsions: Preparation, characterization and its improved inhibitory effect on nitric oxide synthase-1. <i>Nitric Oxide - Biology and Chemistry</i> , 2018, 76, 129-135.	1.2	5
12	Solid-state compatibility studies of a drug without melting point. <i>Journal of Thermal Analysis and Calorimetry</i> , 2018, 131, 3201-3209.	2.0	13
13	Cyclodextrin based nanosponge of norfloxacin: Intestinal permeation enhancement and improved antibacterial activity. <i>Carbohydrate Polymers</i> , 2018, 195, 586-592.	5.1	40
14	Intestinal permeability determinants of norfloxacin in Ussing chamber model. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 121, 236-242.	1.9	19
15	Self-Nanoemulsified Drug Delivery System of Hydrochlorothiazide for Increasing Dissolution Rate and Diuretic Activity. <i>AAPS PharmSciTech</i> , 2017, 18, 2494-2504.	1.5	14
16	Chitosan microencapsulation of the dispersed phase of an O/W nanoemulsion to hydrochlorothiazide delivery. <i>Journal of Microencapsulation</i> , 2017, 34, 611-622.	1.2	8
17	Physicochemical characterization of dipeptidyl peptidase-4 inhibitor alogliptin in physical mixtures with excipients. <i>Journal of Thermal Analysis and Calorimetry</i> , 2017, 130, 1575-1584.	2.0	3
18	Inclusion complexes of hydrochlorothiazide and β -cyclodextrin: Physicochemical characteristics, in vitro and in vivo studies. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 83, 71-78.	1.9	27

#	ARTICLE	IF	CITATIONS
19	Quantitative Analysis of Norfloxacin in β -Cyclodextrin Inclusion Complexes Development and Validation of a Stability-indicating HPLC Method. <i>Analytical Sciences</i> , 2015, 31, 1083-1089.	0.8	12
20	Investigation of β -cyclodextrin-norfloxacin inclusion complexes. Part 1. Preparation, physicochemical and microbiological characterization. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 119-129.	2.0	14
21	Investigation of β -cyclodextrin-norfloxacin inclusion complexes. Part 2. Inclusion mode and stability studies. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 131-140.	2.0	11
22	Fluconazole excipient compatibility studies as the first step in the development of a formulation candidate for biowaiver. <i>Journal of Thermal Analysis and Calorimetry</i> , 2015, 120, 771-781.	2.0	22
23	Physicochemical and microbiological stability studies of extemporaneous antihypertensive pediatric suspensions for hospital use. <i>Pharmaceutical Development and Technology</i> , 2013, 18, 813-820.	1.1	16
24	Formulation Development and Stability Studies of Norfloxacin Extended-Release Matrix Tablets. <i>BioMed Research International</i> , 2013, 2013, 1-9.	0.9	13
25	Liquid chromatographic determination of lumiracoxib in pharmaceutical formulations. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2010, 51, 728-732.	1.4	4
26	Physico-chemical solid-state characterization of omeprazole sodium: Thermal, spectroscopic and crystallinity studies. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2009, 49, 72-80.	1.4	25
27	Liquid Chromatographic Determination of Norfloxacin in Extended-Release Tablets. <i>Journal of Chromatographic Science</i> , 2009, 47, 739-744.	0.7	12
28	Comparator product issues for biowaiver implementation: the case of Fluconazole. <i>Brazilian Journal of Pharmaceutical Sciences</i> , 0, 58, .	1.2	0